Created at	Source	Raw Value	Validated value
May 7, 2022, 5 a.m.	usa	Percentage of participants discontinuing from study therapy due to AE;Percentage of participants who have undetectable SARS-CoV-2 in baseline nasopharyngeal (NP) swabs and develop COVID-19 (laboratory-confirmed SARS-CoV-2 infection with symptoms) through Day 14;Percentage of participants with ≥1 adverse event	Percentage of participants discontinuing from study therapy due to AE;Percentage of participants who have undetectable SARS-CoV-2 in baseline nasopharyngeal (NP) swabs and develop COVID-19 (laboratory-confirmed SARS-CoV-2 infection with symptoms) through Day 14;Percentage of participants with ≥1 adverse event
Feb. 17, 2022, 5 p.m.	usa	Percentage of participants discontinuing from study therapy due to AE;Percentage of participants who have undetectable SARS-CoV-2 in baseline NP swabs and develop COVID-19 (laboratory-confirmed SARS-CoV-2 infection with symptoms) through Day 14;Percentage of participants with ≥1 adverse event	Percentage of participants discontinuing from study therapy due to AE;Percentage of participants who have undetectable SARS-CoV-2 in baseline NP swabs and develop COVID-19 (laboratory-confirmed SARS-CoV-2 infection with symptoms) through Day 14;Percentage of participants with ≥1 adverse event
June 27, 2021, 2:30 a.m.	usa	Percentage of participants discontinuing from study therapy due to AE;Percentage of participants with ≥1 adverse event;Percentage of participants with COVID-19 (laboratory-confirmed severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] infection with symptoms) through Day 14	Percentage of participants discontinuing from study therapy due to AE;Percentage of participants with ≥1 adverse event;Percentage of participants with COVID-19 (laboratory-confirmed severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] infection with symptoms) through Day 14